Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
01 oct. 2021 16h00 HE
|
Adverum Biotechnologies, Inc.
-- Results featured in a presentation today at the Retina Society’s 54th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction...
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
27 sept. 2021 09h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
23 août 2021 09h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Second Quarter 2021 Results
05 août 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
22 juil. 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host...
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
01 juil. 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Announces Changes to Management Team
24 juin 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO -- -- Leone Patterson departs as president and CFO after five years of service -- REDWOOD CITY, Calif., June 24,...
Adverum Appoints CMO and CSO
01 juin 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
-- Julie Clark, M.D., appointed chief medical officer -- -- Brigit Riley, Ph.D., appointed chief scientific officer – REDWOOD CITY, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Adverum...
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
12 mai 2021 13h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
10 mai 2021 08h15 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...